Interactive Brokers Advertisement
Home > Boards > US OTC > Medical - Healthcare >

Theralase Technologies Inc. (TLTFF)

Add TLTFF Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 6/26/2017 7:38:44 AM - Followers: 67 - Board type: Free - Posts Today: 2


Jan 22, 2014 7:20 AM | about stocks: TLTFF


Theralase Technologies Inc. (TSX-V: TLT, US-OTCBB: TLTFF). They design, develop, manufacture and market, patented, super-pulsed laser technology used in biostimulative and biodestructive clinical applications. The Theralase technology platform targets several health-care sectors: First, for non-invasive pain management and clinical therapy, used in neural muscular skeletal conditions, including arthritis and osteoarthritis; Second, wound care and healing (including non-healing fractures and bone fracture regeneration); And third, research and development into combining patented photodynamic compounds (PDCs) with patented, super-pulsed, biofeedback laser technology to attack specifically targeted cancers, bacteria and viruses.

The company is currently focused on the commercialization (production, marketing and distribution) of the TLC-2000 Superpulsed Laser Technology to healthcare practitioners, and commercialization of the patented TLC-3000 Photo Dynamic Compound Cancer Technology through pre-clinical research and clinical trials.

Key Investment Highlights:

  • Working on breakthrough bladder cancer destruction technology and has achieved tremendous success in pre-clinical trials
    Proven clinical technology (TLC-1000) and commercial therapeutic laser business and brand developed over last 17 years, currently generating ~2M of revenue annually
    Rollout of new TLC-2000 technology in 2014, along with a new recurring revenue business model
    Strategic agreements in place with world renowned institutions to help advance research and mitigate expenses
    Competitive technical advantages (Cellular pathways: iNOS, ATP, Na+ / K+)
    Future technology (patented biofeedback technology and patented PDC cancer destruction)
    IP protection (multiple issued patents)
    Large addressable US markets ($ billions)
    No debt
    Positive cash flow / double digit growth
    Lots of opportunity for short-term and long-term growth (revenue & profit)
    Experienced management team (20+ years)
    Clear vision and execution strategy


Theralase has patented anti-cancer drugs known as Photo Dynamic Compounds (PDCs) which localize the DNA of cancer cells and when irradiated, destroy the DNA resulting in apoptosis (natural cell death). While PDCs are used in Photodynamic Therapy (PDT) as a potential treatment regime for a number of conditions, Theralase has discovered that they hold particular promise as treatment to particular cancers. Theralase PDCs have proven successful in destroying breast, colon, brain and bladder cancer cells. Recent lab results have shown that Theralase was able to completely destroy subcutaneous bladder cancer tumors in mouse models. "The achievement of this important milestone signifies that Theralase's leading drug candidate is effective in the destruction of cancer in a live animal model and can prevent the cancer from recurring," commented Roger White of Theralase.

Key Market Statistics:

  • US bladder cancer treatment annual spending was $3.9 billion in 2012
    70,000 new cases, > 14,000 deaths in the US each year
    386,000 new cases are diagnosed worldwide annually
    Standard treatment unchanged with no new drugs approved since 1998
    5th most common cancer, 4th in men, 8th in women
    Most expensive cancer to treat with a recurrence rate up to 80%
    70% of new bladder cancer cases are early stage disease and 90% of bladder cancers are Transitional Cell Carcinoma (TCC)

Theralase PDC Characteristics:

  • Up to 100% cancer cell kill at very low concentrations (< 0.8μM)

(click to enlarge)

  • More effective at killing cancer cells than FDA approved drugs

(668,000x ALA, 198x PHOTOFRIN)

  • Survival of mice up to 20 months (50 human years) after one Theralase PDT treatment

(click to enlarge)

We are VERY IMPRESSED, and VERY EXCITED about these results! In 2012, annual spending for bladder cancer treatment in the US was $3.9 billion, and the current standard of care has been unchanged with no new drugs approved since 1998. Bladder cancer is the most expensive cancer to treat, and has a recurrence rate up to 80%. All of the mice which showed an initial response have remained cancer free, healed without scarring, and have developed normally after only one Theralase PDC treatment. Needless to say, the early results from Theralase look extremely positive. Imagine being able to not only provide treatment for bladder cancer, but to actually cure it, and stop it from coming back! The company is also working on developing further PDCs that can be used to treat a wide variety of other cancers (breast, colon, brain and lung), as well as bacteria and viruses.

  • The general patent protects 1,000s of molecules - essentially a library of PDCs
    Virtually 0% toxicity at high concentrations (> 100μM) leading to ultra-high safety profile
    Activated by laser light providing excellent specificity and selectivity
    Able to treat solid core hypoxic tumors, such as: breast, prostate and lung
    Research outsourced to and performed at world renowned Princess Margaret Cancer Centre
    Patented under numerous US and International Patents:
    Issued USA Patents: 6,962,910, 7,612,057, 8,148,360, 8,445,475
    Pending USA Patent Applications: 61/801,674, 13/863,089, 13/36595

To help explain how the procedure works we sketched a diagram:

(click to enlarge)

  1. A catheter is inserted into the patient
    The PDC is injected and saturates within the patient's bladder, penetrating the cellular membrane (DNA localizing)
    Fiber optics cables are inserted up the catheter into the bladder
    Using laser technology, light is irradiated 360°
    The entire procedure takes about 2 - 3 hours

Theralase is currently completing the validation of the orthotopic rat model, a dose toxicity study, GMP drug manufacture, and FDA Investigational New Drug (IND) application. The next phase is to complete an FDA phase 1/2a human clinical study with FDA breakthrough status, and then to execute a strategic partnership agreement with big pharmaceutical (pharma) company (upfront payments, co-development funds, annual recurring revenue streams).

Industry comparables:

(click to enlarge)

(click to enlarge)

Deals with comparable big pharma companies have yielded anywhere from $466M to $1B plus royalties.


The thing is, by the time clinical trials have been completed (assuming they're successful), Theralase will be trading many multiples higher than today. Look how excited investors got when Theralase first released PDC breast cancer results during January 2010, the intraday high for TLT was $1.39/share:

Read More :

Themes: Biotechnology, Micro Capitalization, Growth Opportunity, Pharmaceuticals, Cancer, Laser Technology, Photo Dynamic Compounds (PDCs) Stocks: TLTFF
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
TLTFF News: Theralase Demonstrates 18 Month Stability of Lead Anti-Cancer Drug 03/15/2017 07:02:00 AM
TLTFF News: Theralase Anti-Cancer Technology Picks Up Steam 01/06/2015 07:00:00 AM
TLTFF News: Theralase CEO to Be Interviewed Today on Clear Channel Business Talk Radio DFW 1190AM 03/12/2014 07:05:00 AM
TLTFF News: Theralase Achieves Commercialization Milestone For Its Bladder Cancer Therapy 03/14/2013 07:00:04 AM
#2895   Nice, need some big ones this week MIKE22CA 06/26/17 07:38:44 AM
#2894   Theralase Researcher Granted Second US Patent for Novel CUIN2 06/26/17 07:12:52 AM
#2893   the problem with this stock is there is heavymetal 06/25/17 11:01:52 AM
#2892   if the higher dose on 6 new patients heavymetal 06/22/17 02:43:36 PM
#2891   Well I hope the trip in New York MIKE22CA 06/20/17 09:17:25 AM
#2890   Something is up with trades that occurred almost CUIN2 06/19/17 08:37:13 PM
#2889   Will be interesting for sure CUIN2 06/15/17 10:31:15 AM
#2888   Well perhaps this climb is the first biggy. MIKE22CA 06/15/17 10:29:01 AM
#2887   tltff on us exchange is up 15% right now. heavymetal 06/15/17 09:37:19 AM
#2886   "LAISSEZ LE BON TEMPS ROULER" heavymetal 06/15/17 08:33:04 AM
#2885   Great news! Today Theralase is in NYC CUIN2 06/15/17 07:59:26 AM
#2884   Theralase Presents Phosphorescent Photosensitizers at International World Congre Anesthesia 2007 06/15/17 07:58:41 AM
#2883   "Dr. Kaspler concluded in his presentation that TLD-1433 is: heavymetal 06/14/17 04:19:36 PM
#2882   Theralase Presents X-Ray Activation at International World Congress Toronto, Anesthesia 2007 06/14/17 09:22:34 AM
#2881 MIKE22CA 06/13/17 09:18:49 PM
#2880   Conclusions of the presentation included: TLD-1433 has good selectivity CUIN2 06/13/17 07:55:01 PM
#2879   I don't think they did. CUIN2 06/13/17 06:49:08 PM
#2878   It's all up from here... End of June MIKE22CA 06/13/17 05:18:33 PM
#2877   I agree! Hopefully we'll see some PR's in Anesthesia 2007 06/13/17 10:39:59 AM
#2876   If they want to finish by december then MIKE22CA 06/13/17 10:31:24 AM
#2875   Not sure, but they will. CUIN2 06/13/17 07:57:57 AM
#2874   I thought this PR was much more informative Anesthesia 2007 06/13/17 07:49:34 AM
#2873   Theralase Presents Dosimetry Planning at International World Congress Accesswir CUIN2 06/13/17 07:21:48 AM
#2872   What can happen between now and the end 123414 06/08/17 06:13:44 AM
#2871   lesson for today: heavymetal 06/03/17 04:31:24 PM
#2870   Back YahooFINANCE Share OTC Markets Group Welcomes Theralase Technologies Inc. t CUIN2 06/02/17 08:05:17 AM
#2869   Interesting rebound starting... MIKE22CA 06/01/17 04:37:53 PM
#2868   On May 26, 2017, Theralase announced that the citoyen 06/01/17 04:21:50 PM
#2867   Pfizer has 5.9 billion shares outstanding @ $32 CUIN2 05/31/17 08:16:35 PM
#2866   It's kinda sad the investors have to be 123414 05/31/17 07:08:31 PM
#2865   Well i hope the patients have a positive LJ Silver 05/31/17 07:08:25 PM
#2864   I expect good results from this trial. The 123414 05/31/17 06:56:34 PM
#2863   I agree. The stockhouse Theralase bullboard has CUIN2 05/31/17 06:43:28 PM
#2862   Proxys about 15 of June? Right now the 123414 05/31/17 06:11:29 PM
#2861   Low dose is half dose .35(therapeutic in preclin) 123414 05/31/17 05:09:21 PM
#2860   just some points to think of suerte88 05/31/17 11:18:37 AM
#2859   Yes CUIN2 05/31/17 10:54:37 AM
#2858   first 3 -> low dose 1/10 of therapeutic dose suerte88 05/31/17 09:13:06 AM
#2857   Is the dose for the next 6 higher LJ Silver 05/31/17 08:40:17 AM
#2856   Theralase Increases Revenue 23% for 1Q2017 Financial Statements Toronto, CUIN2 05/30/17 10:27:14 PM
#2855   well this is a surprise. heavymetal 05/30/17 12:34:01 PM
#2854   Yes I agree suerte88 05/30/17 11:15:14 AM
#2853   Or just hold CUIN2 05/30/17 11:00:15 AM
#2852   Yes, that real information about the cancer treament suerte88 05/30/17 10:40:30 AM
#2851   WTH is going on?! Are we in some Anesthesia 2007 05/30/17 10:35:23 AM
#2850   For those who are new to the knowledge heavymetal 05/30/17 06:51:07 AM
#2849   We aren't insiders (at least I am not) CUIN2 05/29/17 10:09:17 PM
#2848   Agree with no dilution. robertshao 05/29/17 09:46:44 PM
#2847   Yeah, brand new poster,maybe basement boy BisexualJoe's cousin? robertshao 05/29/17 09:38:08 PM
#2846   dilution? i don't think so. heavymetal 05/29/17 03:13:15 PM